Lifshitz Law Firm Announces Investigation of Atossa Genetics, Inc., Francesca's Holdings Corporation, Greenway Medical Technologies, Inc., and PVR Partners, L.P.

NEW YORK, Oct. 12, 2013 /PRNewswire/ --

Atossa Genetics, Inc.
Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty by the board of directors of Atossa Genetics, Inc. ("Atossa" or the "Company"). On October 4, 2013, Atossa announced it had commenced the voluntary recall of the ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test. In February 2013, the Company received a warning letter from the FDA. The FDA raised concerns about (1) the current instructions for use ("IFU"); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA's concerns are addressed.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] Ext. 18 or by sending an e-mail including your contact information to: [e-mail].

Francesca's Holdings Corporation
Lifshitz Law Firm announces that a class action suit was filed in the United States District Court for the Southern District of New York, alleging that Francesca's Holdings Corporation ("FRAN") issued false and misleading statements to investors between March 20, 2013 and September 3, 2013, inclusive (the "Class Period") by failing to disclose that: (i) spring and summer weather and a competitive back-to-school retail environment weighed on same-store sales growth; and (ii) same-store sales were declining.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] Ext. 18 or by sending an e-mail including your contact information to: [e-mail].

Greenway Medical Technologies, Inc.
Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Greenway Medical Technologies, Inc. ("GWAY") to Vista Equity Partners in a transaction valued at approximately $644 million or $20.35 per share in cash.

Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to GWAY's shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] Ext. 18 or by sending an e-mail including your contact information to: [e-mail].

PVR Partners, L.P.
Lifshitz Law Firm announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of PVR Partners, L.P. ("PVR") to Regency Energy Partners LP in a unit-for-unit transaction plus a one-time cash payment to PVR unitholders that collectively imply a value on October 10, 2013 for PVR of approximately $5.6 billion, including the assumption of net debt of $1.8 billion.

Lifshitz Law Firm's investigation is focused on whether the proposed deal provides adequate value to PVR's shareholders.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] Ext. 18 or by sending an e-mail including your contact information to: [e-mail].

Lifshitz Law Firm is a New York based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit our website at www.jlclasslaw.com.

ATTORNEY ADVERTISING. © 2013 Lifshitz Law Firm. The law firm responsible for this advertisement is Lifshitz Law Firm, 18 East 41^st Street, New York, New York 10017, [phone]. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law Firm
Phone: [phone]
Email: [e-mail]

SOURCE Lifshitz Law Firm